Table 3 Milk-derived EVs in tumor
From: Emerging applications of extracellular vesicles in tumor therapy
Source | Therapeutic agent | Targeting tumors/cells | Research models | Tumor cell lines | Outcomes | References |
|---|---|---|---|---|---|---|
Milk | – | Colon cancer and breast cancer | In vivo/in vitro | 4T1.2, LIM1215 and MCF7 | Induced the senescence of tumor cells and reduced the primary tumor load in the body, but increased the metastasis of tumors | Samuel et al. (2021) |
Milk | Curcumin | Colon adenocarcinoma | In vitro | Caco-2 | Increased stability, solubility and bioavailability of curcumin | Vashisht et al. (2017) |
Turing milk | DPAICP | Malignant melanoma, lung cancer and colon cancer | In vivo | - | Restored the p53 signaling pathway, further activating T cells and enhanced anti-PD1 immunotherapy | He et al. (2022) |
Goat milk | PTT and ICG | Colon Cancer | In vivo/in vitro | MC38 | Triggered anti-tumor immune and inflammatory responses to enhance PTT | Jing et al. (2023) |